Shenzhen Hepalink Pharmaceutical Co Ltd

Hepalink released its 2026 interim report. Total operating revenue was 2.58 billion yuan, down 8.44% from the same period last year. Net profit attributable to the parent company was 275 million yuan, down 34.74% year on year. Net cash inflow from operating activities was 815 million yuan, down 22.34% year on year. The company's asset-liability ratio was 26.52%, gross margin was 34.20%, return on equity was 2.31%, and diluted earnings per share was 0.19 yuan. The number of shareholders was 24,000, and the top ten shareholders held 85.91% of the total share capital.

Hepalink released its 2026 interim report, showing first-half net profit attributable to the parent of 275 million yuan, down 34.7% year on year. Operating revenue was 2.58 billion yuan, down 8.4% year on year. Net profit attributable to the parent after deducting non-recurring items was 162 million yuan, down 62.01% year on year. Net operating cash flow was 815 million yuan, down 22.3% year on year. Earnings per share were 0.1876 yuan. In the second quarter, operating revenue was 1.25 billion yuan, down 12.3% year on year, and net profit attributable to the parent was 87.71 million yuan, down 66.9% year on year. As of the end of the second quarter, total assets were 16.307 billion yuan, down 2.0% from the end of the previous year, and net assets attributable to the parent were 11.934 billion yuan, down 0.8% from the end of the previous year. The company said its main businesses cover the heparin supply chain, biologics CDMO, and investment, development and commercialization of innovative drugs. Sales volume of enoxaparin sodium preparations achieved double-digit year-on-year growth, but CDMO revenue declined due to the completion and delivery of some contracts and the early stage of cooperation with new clients.